000112460 001__ 112460
000112460 005__ 20240207145454.0
000112460 0247_ $$2doi$$a10.3390/biomedicines9060612
000112460 0248_ $$2sideral$$a127260
000112460 037__ $$aART-2021-127260
000112460 041__ $$aeng
000112460 100__ $$aGracia Rubio, Irene
000112460 245__ $$aSR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies
000112460 260__ $$c2021
000112460 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112460 5203_ $$aHigh plasma level of low-density lipoprotein (LDL) is the main driver of the initiation and progression of cardiovascular disease (CVD). Nevertheless, high-density lipoprotein (HDL) is con-sidered an anti-atherogenic lipoprotein due to its role in reverse cholesterol transport and its ability to receive cholesterol that effluxes from macrophages in the artery wall. The scavenger receptor B class type 1 (SR-B1) was identified as the high-affinity HDL receptor, which facilitates the selective uptake of cholesterol ester (CE) into the liver via HDL and is also implicated in the plasma clearance of LDL, very low-density lipoprotein (VLDL) and lipoprotein(a) (Lp(a)). Thus, SR-B1 is a multifunc-tional receptor that plays a main role in the metabolism of different lipoproteins. The aim of this review is to highlight the association between SR-B1 and CVD risk through mice and human genetic studies.
000112460 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B14-7R$$9info:eu-repo/grantAgreement/ES/ISCIII/CD19-00245$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI19-00694$$9info:eu-repo/grantAgreement/ES/MICINN-ISCIII/PI18-01777
000112460 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000112460 590__ $$a4.757$$b2021
000112460 592__ $$a0.874$$b2021
000112460 594__ $$a3.0$$b2021
000112460 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000112460 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b121 / 297 = 0.407$$c2021$$dQ2$$eT2
000112460 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2021$$dQ1
000112460 591__ $$aPHARMACOLOGY & PHARMACY$$b87 / 279 = 0.312$$c2021$$dQ2$$eT1
000112460 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b62 / 139 = 0.446$$c2021$$dQ2$$eT2
000112460 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112460 700__ $$aMartín, C.
000112460 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, Fernando$$uUniversidad de Zaragoza
000112460 700__ $$aCenarro, Ana
000112460 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000112460 773__ $$g9, 6 (2021), 612 [18 pp.]$$tBiomedicines$$x2227-9059
000112460 8564_ $$s1316986$$uhttps://zaguan.unizar.es/record/112460/files/texto_completo.pdf$$yVersión publicada
000112460 8564_ $$s2748571$$uhttps://zaguan.unizar.es/record/112460/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112460 909CO $$ooai:zaguan.unizar.es:112460$$particulos$$pdriver
000112460 951__ $$a2024-02-07-14:52:16
000112460 980__ $$aARTICLE